Should I buy or sell Cipher Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cipher Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CPH shares. View CPH analyst ratings or view top-rated stocks .

What is Cipher Pharmaceuticals' stock price target for 2024?

1 Wall Street research analysts have issued 12 month price targets for Cipher Pharmaceuticals' stock. Their CPH share price targets range from C$8.00 to C$8.00. On average, they expect the company's stock price to reach C$8.00 in the next year. This suggests that the stock has a possible downside of 5.9%. View analysts price targets for CPH or view top-rated stocks among Wall Street analysts .

How have CPH shares performed in 2024?

Cipher Pharmaceuticals' stock was trading at C$5.54 at the beginning of 2024. Since then, CPH stock has increased by 53.4% and is now trading at C$8.50. View the best growth stocks for 2024 here .

When is Cipher Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our CPH earnings forecast .

How were Cipher Pharmaceuticals' earnings last quarter?

Cipher Pharmaceuticals Inc. (TSE:CPH) released its earnings results on Thursday, March, 14th. The company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.15 by $0.26. The firm earned $6.70 million during the quarter, compared to the consensus estimate of $7.31 million. Cipher Pharmaceuticals had a trailing twelve-month return on equity of 28.19% and a net margin of 96.32%.

What other stocks do shareholders of Cipher Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cipher Pharmaceuticals investors own include Cipher Pharmaceuticals (CPHRF) , Bellatrix Exploration (BXE) , Aurora Cannabis (ACB) , Aldeyra Therapeutics (ALDX) , Allena Pharmaceuticals (ALNA) , Catalyst Biosciences (CBIO) , Crescent Point Energy (CPG) and Enbridge (ENB) .

How do I buy shares of Cipher Pharmaceuticals?

Shares of CPH stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor , Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. Compare Top Brokerages Here .

TSE:CPH

Cipher Pharmaceuticals (CPH) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free CPH Stock Alerts

C$8.50

-0.30 (-3.41%)

(As of 04/19/2024 ET)

Compare

Today's Range: C$8.42
▼
C$8.93
50-Day Range: C$6.41
▼
C$9.50
52-Week Range: C$3.11
▼
C$9.98

Volume: 23,709 shs
Average Volume: 40,816 shs
Market Capitalization: C$203.92 million

P/E Ratio: 7.80
Dividend Yield: N/A
Price Target: C$8.00

Stock Analysis Analyst Forecasts Chart Competitors Earnings Headlines

Get Cipher Pharmaceuticals alerts:

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About Cipher Pharmaceuticals Stock (TSE:CPH)

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company's licensed products comprise Absorica, an oral retinoid indicated for the treatment of f severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Lipofen, which is indicated as adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, and to increase HDL-C, as well as to reduce triglycerides in adult patients; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults. Its pipeline products include MOB-015, a topical formulation of terbinafine, which is in phase 3 clinical trial for treatment of onychomycosis; CF-101 (Piclidenoson) that is in phase 3 clinical trial for severe plaque psoriasis and rheumatoid arthritis; and DTR-001, a tattoo removal cream, which is in pre-clinical stage. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Mississauga, Canada.

CPH Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CPH Stock News Headlines

April 18, 2024 | americanbankingnews.com

Cipher Pharmaceuticals (TSE:CPH) Shares Cross Above Fifty Day Moving Average of $7.92

April 3, 2024 | ca.finance.yahoo.com

Stocks in play: Cipher Pharmaceuticals

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

March 28, 2024 | theglobeandmail.com

Cipher Pharmaceuticals: Top 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (CPH)

March 17, 2024 | seekingalpha.com

Cipher Pharmaceuticals (CPHRF) Q4 2023 Earnings Call Transcript

March 17, 2024 | investing.com

Earnings call: Cipher Pharmaceuticals outlines growth and financials

January 5, 2024 | morningstar.com

Cipher Pharmaceuticals Inc CPH

January 3, 2024 | finance.yahoo.com

Cipher Pharmaceuticals Inc (PHE.MU)

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

November 24, 2023 | finance.yahoo.com

Cipher Pharmaceuticals Announces Change of Auditor

November 24, 2023 | benzinga.com

Cipher Pharmaceuticals Stock (OTC:CPHRF) Dividends: History, Yield and Dates

November 15, 2023 | finance.yahoo.com

Cipher Pharmaceuticals Inc.'s (TSE:CPH) 23% gain last week benefited both individual investors who own 56% as well as insiders

October 27, 2023 | finance.yahoo.com

Cipher Pharmaceuticals Schedules Q3 2023 Earnings Release and Conference Call

September 5, 2023 | finance.yahoo.com

Cipher Pharmaceuticals Announces Intention to Commence Substantial Issuer Bid, Aggregate Price up to $6 Million Canadian Dollars

August 10, 2023 | finance.yahoo.com

Cipher Pharmaceuticals Releases Q2 2023 Results, Announces Launch of Epuris in Mexico

July 28, 2023 | finance.yahoo.com

Cipher Pharmaceuticals Schedules Q2 2023 Earnings Release and Conference Call

July 5, 2023 | finance.yahoo.com

Cipher Partner, Moberg Pharma Announces Approval for MOB-015 in the European Union

June 21, 2023 | finance.yahoo.com

Cipher Pharmaceuticals Announces Results of Annual and Special Meeting of Shareholders

May 4, 2023 | finance.yahoo.com

Cipher Pharmaceuticals Schedules Q1 2023 Earnings Release and Conference Call

April 26, 2023 | theglobeandmail.com

Closing Bell: Cipher Pharmaceuticals Inc flat on Tuesday (CPH)

April 20, 2023 | theglobeandmail.com

Closing Bell: Cipher Pharmaceuticals Inc flat on Thursday (CPH)

April 18, 2023 | finanznachrichten.de

Bloom Burton & Co. Inc.: Cipher Pharmaceuticals to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

April 18, 2023 | theglobeandmail.com

Closing Bell: Cipher Pharmaceuticals Inc up on Tuesday (CPH)

April 18, 2023 | finance.yahoo.com

Cipher Pharmaceuticals to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

April 14, 2023 | theglobeandmail.com

Closing Bell: Cipher Pharmaceuticals Inc up on Friday (CPH)

April 10, 2023 | theglobeandmail.com

Closing Bell: Cipher Pharmaceuticals Inc down on Monday (CPH)

April 6, 2023 | theglobeandmail.com

Closing Bell: Cipher Pharmaceuticals Inc down on Wednesday (CPH)

See More Headlines

Receive CPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cipher Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/14/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: TSE
Sector: Medical
Industry: Drug Manufacturers - Specialty & Generic
Sub-Industry: N/A
Current Symbol: TSE:CPH
Previous Symbol: TSE:DND
CUSIP: N/A
CIK: N/A
Web: www.cipherpharma.com
Phone: +1-905-6025840
Fax: N/A
Employees: 5
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: C$8.00
High Stock Price Target: C$8.00
Low Stock Price Target: C$8.00
Potential Upside/Downside: -5.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): C$1.09
Trailing P/E Ratio: 7.80
Forward P/E Ratio: 14.07
P/E Growth: N/A
Net Income: C$20.38 million
Net Margins: 96.32%
Pretax Margin: N/A
Return on Equity: 28.19%
Return on Assets: 8.06%

Debt

Debt-to-Equity Ratio: 0.44
Current Ratio: 9.19
Quick Ratio: 2.67

Sales & Book Value

Annual Sales: C$21.16 million
Price / Sales: 9.64
Cash Flow: C$2.41 per share
Price / Cash Flow: 3.53
Book Value: C$3.36 per share
Price / Book: 2.53

Miscellaneous

Outstanding Shares: 23,990,000
Free Float: N/A
Market Cap: C$203.92 million
Optionable: Not Optionable
Beta: 0.97

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Craig J. Mull
Interim CEO & Chairman of the Board
Mr. Bryan Jacobs
Chief Financial Officer
Dr. Diane Gajewczyk
Vice President of Scientific & Medical Affairs
Mr. Emilio Presti
Director of Sales & Marketing

Key Competitors

View All Competitors

CPH Stock Analysis - Frequently Asked Questions

Should I buy or sell Cipher Pharmaceuticals stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cipher Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CPH shares.
View CPH analyst ratings or view top-rated stocks.
What is Cipher Pharmaceuticals' stock price target for 2024?: 1 Wall Street research analysts have issued 12 month price targets for Cipher Pharmaceuticals' stock. Their CPH share price targets range from C$8.00 to C$8.00. On average, they expect the company's stock price to reach C$8.00 in the next year. This suggests that the stock has a possible downside of 5.9%.
View analysts price targets for CPH or view top-rated stocks among Wall Street analysts.
How have CPH shares performed in 2024?: Cipher Pharmaceuticals' stock was trading at C$5.54 at the beginning of 2024. Since then, CPH stock has increased by 53.4% and is now trading at C$8.50.
View the best growth stocks for 2024 here.
When is Cipher Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our CPH earnings forecast.

How were Cipher Pharmaceuticals' earnings last quarter?: Cipher Pharmaceuticals Inc. (TSE:CPH) released its earnings results on Thursday, March, 14th. The company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.15 by $0.26. The firm earned $6.70 million during the quarter, compared to the consensus estimate of $7.31 million. Cipher Pharmaceuticals had a trailing twelve-month return on equity of 28.19% and a net margin of 96.32%.
What other stocks do shareholders of Cipher Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cipher Pharmaceuticals investors own include Cipher Pharmaceuticals (CPHRF), Bellatrix Exploration (BXE), Aurora Cannabis (ACB), Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA), Catalyst Biosciences (CBIO), Crescent Point Energy (CPG) and Enbridge (ENB).
How do I buy shares of Cipher Pharmaceuticals?: Shares of CPH stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:CPH) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Cipher Pharmaceuticals (CPH) Stock Price, News & Analysis

About Cipher Pharmaceuticals Stock (TSE:CPH)

CPH Stock Price History

CPH Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

CPH Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info